Variable | Training cohort [n(%)] | Internal validation cohort [n(%)] | External validation cohort [n(%)] | P-value |
---|---|---|---|---|
Age (yrs) | Â | Â | Â | 0.006 |
 ≤ 50 | 255 (44.6%) | 115 (46.7%) | 108 (58.1%) |  |
 > 50 | 317 (55.4%) | 131 (53.3%) | 78 (41.9%) |  |
Marital status |  |  |  | < 0.001 |
 Married | 270 (47.2%) | 116 (47.2%) | 161 (86.6%) |  |
 Other conditions | 302 (52.8%) | 130 (52.8%) | 25 (13.4%) |  |
Differentiation | Â | Â | Â | 0.217 |
 Well | 258 (45.1%) | 107 (43.5%) | 77 (41.4%) |  |
 Moderately | 234 (40.9%) | 104 (42.3%) | 70 (37.6%) |  |
 Poorly | 80 (14.0%) | 35 (14.2%) | 39 (21.0%) |  |
Tumor stage |  |  |  | < 0.001 |
 IA-IB/ Localized | 338 (59.1%) | 148 (60.8%) | 31 (16.7%) |  |
 IC-IIB/ Regional | 155 (27.1%) | 64 (26.0%) | 87 (46.8%) |  |
 III-IV/ Distant | 79 (13.8%) | 34 (13.8%) | 68 (36.6%) |  |
CA125 | Â | Â | Â | 0.011 |
 Negative/Unknown | 282 (49.3%) | 121 (49.2%) | 69 (37.1%) |  |
 Positive | 290 (50.7%) | 125 (50.8%) | 117 (62.9%) |  |
LNM | Â | Â | Â | 0.105 |
 No/No resection | 556 (97.2%) | 234 (95.1%) | 175 (94.1%) |  |
 Positive | 16 (2.8%) | 12 (4.9%) | 11 (5.9%) |  |
Residual Disease |  |  |  | < 0.001 |
 R0 | 517 (90.4%) | 225 (91.5%) | 129 (69.4%) |  |
 R1 | 29 (5.1%) | 11 (4.5%) | 22 (11.8%) |  |
 R2 | 26 (4.5%) | 10 (4.1%) | 35 (18.8%) |  |
Total | 572 (100%) | 246 (100%) | 186 (100%) | Â |